Previous 10 | Next 10 |
2024-06-04 14:46:03 ET Summary Revolution Medicines, Inc. stock has more than doubled since the market initially reacted negatively to a clinical update on its lead asset RMC-6236 in October 2023. The company's RAS(ON) inhibitors will be tested in two registrational trials for pan...
2024-06-04 11:42:04 ET More on BridgeBio Pharma BridgeBio Pharma: Upping An Existing Position (Rating Upgrade) BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident BridgeBio reports additional positive data for acoramidis in AT...
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.50 cm/yr at Month 18 (p=0.0015) - At Month 18...
PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children ...
2024-06-03 14:32:19 ET Summary Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200...
2024-06-03 14:14:05 ET Summary BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently. The company's primary drug candidate, Acoramidis, has a marketing application accepted by the FDA for ...
2024-05-29 20:54:18 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value decreased from $27.3B to $26.9B in Q1 2024. The number of holdings in the portfolio increased from 79 to 83. The largest five individual stock positions are Visa, Workday, Amazon.com, Philip Morri...
2024-05-29 17:11:50 ET More on BridgeBio Pharma BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident Cantor picks 14 undervalued biotech stocks worth a second look BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of ...
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular-related hospitalization (CVH) in ATTR-CM participants through m...
2024-05-28 07:00:15 ET Eliana Merle from UBS issued a price target of $47.00 for BBIO on 2024-05-28 05:24:00. The adjusted price target was set to $47.00. At the time of the announcement, BBIO was trading at $27.94. The overall price target consensus is at $32.25 with hi...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO...